AU2092597A - Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds - Google Patents

Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds

Info

Publication number: AU2092597A
Authority: AU; Australia
Prior art keywords: chemotherapeutic compounds; targeted oligonucleotides; antiproliferative combinations; containing raf; raf
Prior art date: 1996-03-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU20925/97A

Inventor

Karl-Heinz Altmann

Doriano Fabbro

Thomas Geiger

Brett Monia

Marcel Muller

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-07

Filing date

1997-02-24

Publication date

1997-09-22

1997-02-24 Application filed by Novartis AG filed Critical Novartis AG

1997-09-22 Publication of AU2092597A publication Critical patent/AU2092597A/en

Status Abandoned legal-status Critical Current

Links

108091034117 Oligonucleotide Proteins 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
230000001028 anti-proliverative effect Effects 0.000 title 1
230000000973 chemotherapeutic effect Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU20925/97A 1996-03-07 1997-02-24 Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds Abandoned AU2092597A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US61278796A	1996-03-07	1996-03-07
US08612787		1996-03-07
PCT/EP1997/000875 WO1997032604A1 (en)	1996-03-07	1997-02-24	Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds

Publications (1)

Publication Number	Publication Date
AU2092597A true AU2092597A (en)	1997-09-22

Family

ID=24454663

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU20925/97A Abandoned AU2092597A (en)	1996-03-07	1997-02-24	Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds

Country Status (3)

Country	Link
AU (1)	AU2092597A (en)
WO (1)	WO1997032604A1 (en)
ZA (1)	ZA971936B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998008528A1 (en)	1996-08-30	1998-03-05	Biomeasure Incorporated	Method of inhibiting fibrosis with a somatostatin agonist
ES2228119T3 (en) *	1998-10-19	2005-04-01	Methylgene, Inc.	MODULATION OF THE EXPRESSION OF DNA-METHYL-TRANFERASE THROUGH COMBINATION THERAPY.
EP1243290A3 (en) *	1998-10-19	2004-03-17	Methylgene, Inc.	Modulation of gene expression by combination therapy
US6953783B1 (en)	1998-10-19	2005-10-11	Methylgene, Inc.	Modulation of gene expression by combination therapy
AP2001002175A0 (en) *	1998-12-22	2001-06-21	Warner Lambert Co	Combination chemotherapy.
WO2001074346A2 (en) *	2000-04-03	2001-10-11	Hybridon, Inc.	Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes
AU2001270479B2 (en) *	2000-07-18	2005-06-30	Leo Pharma A/S	Matrix metalloproteinase inhibitors
KR20060025141A (en)	2003-05-15	2006-03-20	아르퀼 인코포레이티드	Inhibitors of P38 and methods of using the same
AU2004241093B2 (en) *	2003-05-16	2009-08-27	Idera Pharmaceuticals, Inc.	Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
US7829560B2 (en)	2004-07-08	2010-11-09	Arqule, Inc.	1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
EP2258704A1 (en)	2004-10-19	2010-12-08	ArQule, Inc.	Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
WO2007139943A2 (en) *	2006-05-26	2007-12-06	Ico Therapeutics Inc.	Therapeutic drug combinations and delivery systems comprising c-raf kinase antisense polynucleotides for treating ocular diseases and disorders
EP2125895B1 (en)	2007-02-02	2015-04-08	Vegenics Pty Ltd	Vegf receptor antagonists for treating organ transplant alloimmunity and arteriosclerosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU6080294A (en) *	1992-12-31	1994-08-15	Texas Biotechnology Corporation	Antisense molecules directed against genes of the (raf) oncogene family
WO1994023755A1 (en) *	1993-04-09	1994-10-27	Board Of Regents Of The University Of Nebraska	Novel methods and compositions for the treatment of ras-activated cancer with heterotypic anti-raf antisense oligonucleotides

1997
- 1997-02-24 AU AU20925/97A patent/AU2092597A/en not_active Abandoned
- 1997-02-24 WO PCT/EP1997/000875 patent/WO1997032604A1/en active Application Filing
- 1997-03-06 ZA ZA9701936A patent/ZA971936B/en unknown

Also Published As

Publication number	Publication date
ZA971936B (en)	1997-09-08
WO1997032604A1 (en)	1997-09-12

Publication	Publication Date	Title
AU2093597A (en)	1997-09-16	Chemical compounds
ZA9710314B (en)	1998-05-18	Chemical compounds.
AU2440997A (en)	1997-10-29	Calixpyrroles, calixpyridinopyrroles and calixpyridines
ZA975953B (en)	1998-01-06	Chemical compounds.
AU1492397A (en)	1998-03-26	Desiccant container
ZA975436B (en)	1997-12-22	Chemical Compounds.
ZA975951B (en)	1998-01-06	Chemical compounds.
AU2092597A (en)	1997-09-22	Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
AU5259498A (en)	1998-05-29	Antisense oligonucleotides
AU3340797A (en)	1998-01-21	Modified oligonucleotides
AUPP433398A0 (en)	1998-07-16	Compounds and processes
ZA975079B (en)	1998-01-14	Packet radio systems.
AU4720397A (en)	1998-03-26	Terpenylated diketopiperazines, (drimentines)
AU7104398A (en)	1998-12-08	Conopeptides auia, auib and auic
AU8682998A (en)	1999-06-07	Improvement in chemical analyses
AU3166897A (en)	1998-01-14	Factor vii-binding reagent
EP0678548A3 (en)	1996-09-04	Antimicrobial materials.
AU8228698A (en)	1999-02-08	Porous container
AU9006998A (en)	1999-03-29	Desiccant
AU5960896A (en)	1997-08-11	Oxidation-reduction process
ZA984689B (en)	1999-12-01	Polymeric materials.
AUPP003297A0 (en)	1997-11-20	4,5-diaryloxazole compounds
AU1018897A (en)	1997-07-24	Envelope printing
AU3961899A (en)	1999-11-23	Chemotherapeutic treatment
AU7781698A (en)	1999-01-04	Ammonia oxidation